

01 18F‑FDG
Maps glucose metabolism to help find and monitor cancers; also used in heart viability and certain brain conditions for functional assessment.

Targets PSMA to detect prostate cancer at staging and recurrence, delivering high‑contrast pelvic imaging.

A radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.

Comprehensive OEM and ODM for radiopharmaceuticals: formulation, technology transfer, cGRPP documentation, QC release, compliant packaging, and distribution.

05 New Pipeline & Research Products
Advancing pipeline radiotracers for oncology and neurology, collaborative research, early access, quantification, guideline-aligned protocols.


HKCL specialize in developing and producing high-quality Positron Emission Tomography (PET) radiopharmaceuticals, such as Fluorodeoxyglucose (18F-FDG), Prostate-Specific Membrane Antigen (18F-PSMA), and F-Flutemetamol (18F-FMM).
G12 & 13, Biotech Centre 2, No.11 Science Park West Avenue, Hong Kong Science Park, Shatin, N. T.
(852) 2332 0989
(852) 2332 0979
Hong Kong Cyclotron Laboratories Limited © 2025. All Right Reserved.